Abstract
On the basis of potent anti-hepatitis C virus (HCV) activity of 2′-C-hydroxymethyladenosine, 3′-C-hydroxymethyl-substituted pyrimidine and purine nucleosides as potential anti-HCV agents were designed and synthesized from D-xylose via stereoselective Grignard reaction and conversion of the vinyl into hydroxymethyl group as key steps.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Behrens, S.-E., Tomei, L., and De Francesco, R., Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J., 15, 12–22 (1996).
Christensen, N. K., Petersen, M., Nielsen, P., Jacobsen, J. P., Olsen, C., and Wengel, J., A novel class of oligonucleotide analogs containing 2′-O,3′-C-Linked [3.2.0]bicycloarabino-nucleoside monomers: Synthesis, thermal affinity studies, and molecular modeling. J. Am. Chem. Soc., 120, 5458–5463 (1998).
Couturier, S., Aljarah, M., Gosselin, G., Mathe, C., and Perigaud, C., Synthesis of 3′-deoxy-3′-C-methyl-β-D-ribonucleoside analogs. Tetrahedron, 63, 11260–11266 (2007) and references cited therein.
Eldrup, A. B., Allerson, C. R., Bennett, C. F., Bera, S., Bhat, B., Bhat, N., Bosserman, M. R., Brooks, J., Burlein, C., Carroll, S. S., Cook, P. D., Getty, K. L., MacCoss, M., McMasters, D. R., Olsen, D. B., Prakash, T. P., Prhavc, M., Song, Q., Tomassini, J. E., and Xia, J., Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem., 47, 2283–2295 (2004).
Gordon, C. P. and Keller, P. A., Control of hepatitis C: A medicinal chemistry perspective, J. Med. Chem., 48, 1–20 (2005).
Hattori, H., Nozawa, E., Iino, T., Yoshimura, Y., Shuto, S., Shimamoto, Y., Nomura, M., Fukushima, M., Tanaka, M., Sasaki, T., and Matsuda, A., Nucleosides and nucleotides. 175. structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)cytosine and-uracil. J. Med. Chem., 41, 2892–2902 (1998).
Hoofnagle, J. H., Hepatitis C: the clinical spectrum of disease. Hepatology, 26, 15S–20S (1997).
Lake-Bakaar, G., Current and future therapy for chronic hepatitis C virus liver disease. Curr. Drug Targets Infect. Disord., 3, 247–253 (2003).
Migliaccio, G., Tomassini, J. E., Carroll, S. S., Tomei, L., Altamura, S., Bhat, B., Bartholomew, L., Bosserman, M. R., Ceccacci, A., Colwell, L. F., Cortese, R., De Francesco, R., Eldrup, A. B., Getty, K. L., Hou, X. S., LaFemina, R. L., Ludmerer, S. W., MacCoss, M., McMasters, D. R., Stahlhut, M. W., Olsen, D. B., hazuda, D. J., and Flores, O. A., Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem., 278, 49164–49170 (2003).
Sommadossi, J.-P., 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. PCT Patent Appl. WO 2004002422 A2, 2004.
Szabo, E., Lotz, G., Paska, C., Kiss, A., and Schaff, Z., Viral hepatitis: new data on hepatitis C infection. Pathol. Oncol. Res., 9, 215 (2003).
Yoo, B. N., Kim, H. O., Moon, H. R., Seol, S. K., Jang, S. K., Lee, K. M., and Jeong, L. S., Synthesis of 2-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agent. Bioorg. Med. Chem. Lett., 16, 4190–4194 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pei, X., Choi, W.J., Kim, Y.M. et al. Synthesis of 3′-C-hydroxymethyl-substituted pyrimidine and purine nucleosides as potential anti-hepatitis C virus (HCV) agents. Arch. Pharm. Res. 31, 843–849 (2008). https://doi.org/10.1007/s12272-001-1236-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-001-1236-z